Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data from National Taiwan University advance knowledge in breast cancer
April 22nd, 2008
According to recent research published in the journal Cancer Chemotherapy and Pharmacology, " The two main goals of this phase-I study were to determine the maximum-tolerated dose (MTD) and to characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Lipo-Dox) and paclitaxel (PTX) administered on a 3-week schedule in patients with metastatic breast cancer (MBC) who had previously been treated with anthracycline-based therapy. This phase-I study was performed via a two-staged dose escalation schema." "The initial doses were PLD 30 mg/m(2) and PTX 150 mg/m(2), administered intravenously once every 21 days. The dose of PLD was escalated...
Source: Cancer Weekly (2008-04-22)
|
